long intergenic non-protein coding RNA 2265Genealiases: []
Q-omics provides the consensus-scored LINC02265 profile across patient tissues and cancer cell-line models. LINC02265 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC02265 is differentially expressed in 7, with the highest sampling consensus in LUSC. Additionally, LINC02265 RNA expression shows 10,765 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LUSC, and THYM as cancer lineages where LINC02265 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02265 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02265 survival associations across molecular data types. LINC02265 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02265 RNA expression–survival associations across cancer types. High LINC02265 expression shows unfavorable associations in KIRC, KICH, THCA and TGCT, but favorable associations in BRCA and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC02265 RNA expression.
This table summarizes LINC02265 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02265. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02265 shows lower tumor expression in LUSC, LUAD, THCA, COAD and UCEC and higher tumor expression in HNSC. The LUSC box plot shows higher LINC02265 RNA expression in normal versus tumor tissue (log2 FC = −0.970, t-test p < 0.001).
This table shows molecular features associated with LINC02265 in patient tissues and cancer cell lines. In patient samples, LINC02265 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
